Appeals Court restricts abortion drug pending SCOTUS review

by ian


Pro-life Americans have reason to celebrate after an appeals court upheld a decision that may save up to 140,000 babies each year.

The 5th U.S. Circuit Court of Appeals partially upheld a lower court decision Wednesday. While the abortion drug mifepristone will remain on the market, the judges say mail-delivery of the drug must end.

The order also rolls back Food and Drug Administration safety guidelines to pre-2016 standards. This makes the drug illegal to take after the 7th week of pregnancy and reinstates reporting of adverse events after taking the drug.

In a sharp rebuke, the three-judge panel says the FDA “failed to consider the cumulative effect of removing several important safeguards at the same time.”

Unfortunately, the Supreme Court needs to review the ruling before it takes effect. That won’t happen until at least October. But if it’s approved, pro-life advocates say it could cut abortions in the U.S. by as much as 15%. That would protect about 140,000 babies annually.